bioAffinity Technologies Files 8-K
Ticker: BIAFW · Form: 8-K · Filed: Oct 28, 2025 · CIK: 1712762
Sentiment: neutral
Topics: 8-K, disclosure, financials
Related Tickers: BIAF
TL;DR
BIAF filed an 8-K on 10/28/25 covering other events and financials.
AI Summary
On October 28, 2025, bioAffinity Technologies, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant business occurrences. No specific financial figures or new events were detailed in the provided excerpt.
Why It Matters
This filing signals that bioAffinity Technologies, Inc. is providing updated information to the SEC, which could include material business events or financial disclosures relevant to investors.
Risk Assessment
Risk Level: low — The filing is a routine disclosure and does not contain information that inherently increases risk.
Key Players & Entities
- bioAffinity Technologies, Inc. (company) — Registrant
- October 28, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-41463 (commission_file_number) — SEC File Number
- 46-5211056 (ein) — I.R.S. Employer Identification Number
- 3300 Nacogdoches Road, Suite 216 (address) — Principal executive offices
- San Antonio, Texas 78217 (address) — Principal executive offices
- 210-698-53 (phone_number) — Business phone
FAQ
What specific "Other Events" are being reported by bioAffinity Technologies, Inc. in this 8-K filing?
The provided excerpt does not detail the specific "Other Events" being reported, only that this item is included in the filing.
What is the nature of the "Financial Statements and Exhibits" mentioned in the 8-K?
The excerpt indicates that financial statements and exhibits are part of the filing, but does not specify their content or any new financial information.
When was this 8-K report filed with the SEC?
The report was filed on October 28, 2025.
What is bioAffinity Technologies, Inc.'s principal executive office address?
The principal executive offices are located at 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217.
What is the Commission File Number for bioAffinity Technologies, Inc.?
The Commission File Number for bioAffinity Technologies, Inc. is 001-41463.
Filing Stats: 536 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2025-10-28 08:30:24
Key Financial Figures
- $0.007 — ch registered Common Stock, par value $0.007 per share BIAF The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 44KB
- ex99-1.htm (EX-99.1) — 14KB
- ex99-1_001.jpg (GRAPHIC) — 30KB
- 0001493152-25-019829.txt ( ) — 310KB
- biaf-20251028.xsd (EX-101.SCH) — 4KB
- biaf-20251028_def.xml (EX-101.DEF) — 26KB
- biaf-20251028_lab.xml (EX-101.LAB) — 36KB
- biaf-20251028_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 28, 2025 BIOAFFINITY TECHNOLOGIES, INC. By: /s/ Maria Zannes Name: Maria Zannes Title: President and Chief Executive Officer -3-